Tarsus Pharmaceuticals Inc (TARS) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

TARS ranks #2396 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

260 institutions disclose a position in TARS, but none treat it as a major bet — even Tang Capital Management LLC, its most concentrated holder, allocates just 4.5% of its own portfolio to it.

Israel Englander has added to its TARS position for two straight quarters, increasing it by $80.5M to reach $91.7M today.

Jennison Associates LLC has trimmed its TARS position for two straight quarters, cutting it by $77.9M while still holding $104.7M.

TARS is down 0.2% today, but institutions show net buying of $366.3M this quarter — a divergence between today's price move and the underlying institutional flow.

TARS reported a net loss of $46.5M over the trailing twelve months.

• Not yet profitable — net loss of $46.5M over the trailing twelve months
• Revenue grew 105.2% year over year
• Net income improved year over year, from -$92.0M to -$46.5M
• Operating cash flow was negative, using $12.5M in cash
• Current ratio of 3.85x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.64x equity — within a conventional range